WO2002085926A3 - Verfahren zur herstellung stabiler, regenerierbarer antikörper-arrays - Google Patents

Verfahren zur herstellung stabiler, regenerierbarer antikörper-arrays Download PDF

Info

Publication number
WO2002085926A3
WO2002085926A3 PCT/EP2002/004311 EP0204311W WO02085926A3 WO 2002085926 A3 WO2002085926 A3 WO 2002085926A3 EP 0204311 W EP0204311 W EP 0204311W WO 02085926 A3 WO02085926 A3 WO 02085926A3
Authority
WO
WIPO (PCT)
Prior art keywords
regeneratable
producing stable
antibody arrays
antibody
arrays
Prior art date
Application number
PCT/EP2002/004311
Other languages
English (en)
French (fr)
Other versions
WO2002085926A2 (de
Inventor
Juergen Wehland
Ronald Frank
Original Assignee
Biotechnolog Forschung Gmbh
Juergen Wehland
Ronald Frank
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotechnolog Forschung Gmbh, Juergen Wehland, Ronald Frank filed Critical Biotechnolog Forschung Gmbh
Priority to EP02745239A priority Critical patent/EP1379545A2/de
Priority to US10/475,147 priority patent/US20040171068A1/en
Priority to JP2002583452A priority patent/JP2004536290A/ja
Publication of WO2002085926A2 publication Critical patent/WO2002085926A2/de
Publication of WO2002085926A3 publication Critical patent/WO2002085926A3/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/14—Peptides being immobilised on, or in, an inorganic carrier

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Die Erfindung betrifft ein Verfahren zur Herstellung stabiler, regenerierbarer antikörper- Arrays unter Verwendung von immobilisierten Antikörperbindungsproteinen, die spezifisch den Fc-Teil von antikörpern erkennen können.
PCT/EP2002/004311 2001-04-19 2002-04-18 Verfahren zur herstellung stabiler, regenerierbarer antikörper-arrays WO2002085926A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02745239A EP1379545A2 (de) 2001-04-19 2002-04-18 Verfahren zur herstellung stabiler, regenerierbarer antikörper-arrays
US10/475,147 US20040171068A1 (en) 2001-04-19 2002-04-18 Method for producing stable, regeneratable antibody arrays
JP2002583452A JP2004536290A (ja) 2001-04-19 2002-04-18 安定した、再生可能な抗体アレイの作製方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10119308.4 2001-04-19
DE10119308 2001-04-19
DE10162365 2001-12-18
DE10162365.8 2001-12-18

Publications (2)

Publication Number Publication Date
WO2002085926A2 WO2002085926A2 (de) 2002-10-31
WO2002085926A3 true WO2002085926A3 (de) 2003-11-06

Family

ID=26009128

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/004311 WO2002085926A2 (de) 2001-04-19 2002-04-18 Verfahren zur herstellung stabiler, regenerierbarer antikörper-arrays

Country Status (4)

Country Link
US (1) US20040171068A1 (de)
EP (1) EP1379545A2 (de)
JP (1) JP2004536290A (de)
WO (1) WO2002085926A2 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7736909B2 (en) * 2003-01-09 2010-06-15 Board Of Regents, The University Of Texas System Methods and compositions comprising capture agents
EP1599597B1 (de) * 2003-02-24 2010-08-04 Pritest, Inc. Lichtdurchlässige festmatrix-prüfvorrichtung zur mikroarray-analyse
WO2006030826A1 (ja) * 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
EP1925676A4 (de) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd Testverfahren für die wirkung eines vaskularisierungsinhibitors
JPWO2007052849A1 (ja) 2005-11-07 2009-04-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質とｃ−ｋｉｔキナーゼ阻害物質との併用
WO2007136103A1 (ja) * 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
WO2007141699A1 (en) * 2006-06-02 2007-12-13 Koninklijke Philips Electronics N. V. Device and method to detect analytes
WO2008026748A1 (fr) * 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
CN101600694A (zh) * 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
NZ581742A (en) 2007-06-08 2012-09-28 Biogen Idec Inc Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
CA2704000C (en) * 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
RU2563822C2 (ru) * 2009-05-29 2015-09-20 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Пептоидные лиганды для выделения и обработки аутоиммунных т-клеток
AU2010256880B2 (en) * 2009-06-02 2015-01-22 Opko Health, Inc. Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases
TW201124726A (en) * 2009-10-16 2011-07-16 Univ Texas Compositions and methods for producing coded peptoid libraries
MX2012014776A (es) 2010-06-25 2013-01-29 Eisai R&D Man Co Ltd Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados.
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
EP2714937B1 (de) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarker zur vorhersage und beurteilung des ansprechens von schilddrüsen- und nierenkrebspatienten auf lenvatinibverbindungen
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
JP6411379B2 (ja) 2013-05-14 2018-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
CN107428818A (zh) 2015-01-29 2017-12-01 密西根州立大学校董会 隐藏多肽及其用途
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN112567246A (zh) 2018-01-25 2021-03-26 比奥根Ma公司 治疗脊髓性肌萎缩症的方法
SG11202010092XA (en) 2018-04-13 2020-11-27 Incyte Corp Biomarkers for graft-versus-host disease
US20210333281A1 (en) 2018-10-05 2021-10-28 Eisai R&D Management Co., Ltd. Biomarkers for a therapy comprising a sorafenib compound
US20210349097A1 (en) 2018-10-05 2021-11-11 Eisai R&D Management Co., Ltd. Biomarkers for a combination therapy comprising lenvatinib and everolimus
EP3924739A1 (de) 2019-02-12 2021-12-22 Biogen MA Inc. Biomarker von progressiver multifokaler leukoenzephalopathie
JP2022526301A (ja) 2019-03-19 2022-05-24 インサイト・コーポレイション 尋常性白斑のバイオマーカー
US20210123931A1 (en) 2019-10-10 2021-04-29 Incyte Corporation Biomarkers for graft-versus-host disease
CA3157499A1 (en) 2019-10-10 2021-04-15 Incyte Corporation Biomarkers for graft-versus-host disease
WO2022047419A1 (en) 2020-08-31 2022-03-03 City Of Hope Novel cell lines, methods of producing natural killer cells and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5243040A (en) * 1987-11-20 1993-09-07 Creative Biomolecules DNA encoding a protein which enables selective removal of immune complexes
WO1997025616A1 (en) * 1996-01-11 1997-07-17 Australian Membrane And Biotechnology Research Institute Ion channel sensor typing
WO2000004389A2 (en) * 1998-07-14 2000-01-27 Zyomyx, Inc. Arrays of protein-capture agents and methods of use thereof
WO2001009607A1 (en) * 1999-07-30 2001-02-08 Large Scale Proteomics, Corp. Microarrays and their manufacture

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620845A (en) * 1988-06-06 1997-04-15 Ampcor, Inc. Immunoassay diagnostic kit

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5243040A (en) * 1987-11-20 1993-09-07 Creative Biomolecules DNA encoding a protein which enables selective removal of immune complexes
WO1997025616A1 (en) * 1996-01-11 1997-07-17 Australian Membrane And Biotechnology Research Institute Ion channel sensor typing
WO2000004389A2 (en) * 1998-07-14 2000-01-27 Zyomyx, Inc. Arrays of protein-capture agents and methods of use thereof
WO2001009607A1 (en) * 1999-07-30 2001-02-08 Large Scale Proteomics, Corp. Microarrays and their manufacture

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FASSINA G ET AL: "PROTEIN A MIMETIC PEPTIDE LIGAND FOR AFFINITY PURIFICATION OF ANTIBODIES", JOURNAL OF MOLECULAR RECOGNITION, HEYDEN & SON LTD., LONDON, GB, vol. 9, no. 5/6, 1 September 1996 (1996-09-01), pages 564 - 569, XP002064544, ISSN: 0952-3499 *

Also Published As

Publication number Publication date
WO2002085926A2 (de) 2002-10-31
EP1379545A2 (de) 2004-01-14
JP2004536290A (ja) 2004-12-02
US20040171068A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
WO2002085926A3 (de) Verfahren zur herstellung stabiler, regenerierbarer antikörper-arrays
WO2003029458A3 (de) Verfahren zur herstellung von protein-bibliotheken und zur selektion von proteinen daraus
WO2003074679A3 (en) Antibody optimization
WO2003062375A3 (en) Stabilizing polypeptides which have been exposed to urea
WO2004099249A3 (en) Optimized fc variants and methods for their generation
WO2006050280A3 (en) Anti-respiratory syncytial virus antibodies, antigens and uses thereof
WO2004029207A3 (en) Optimized fc variants and methods for their generation
AU2001268855A1 (en) Single-domain antigen-binding antibody fragments derived from llama antibodies
EA200700917A1 (ru) Способ рефолдинга рекомбинантных антител
WO2003102132A3 (en) Non-affinity purification of proteins
EP2270045B8 (de) Antikörper gegen Clostridium difficile Toxine und ihre Verwendung
WO2003087129A3 (en) Immunogenic peptides, and method of identifying same
WO2001004144A3 (de) Design von beta-faltblatt-proteinen mit spezifischen bindungseigenschaften
WO2005121177A3 (en) Anti-il-13 antibodies, crystals of anti-il-13 antibodies and complexes comprising them
WO2005073732A3 (en) Lc/ms method of analyzing high molecular weight proteins
MXPA03008031A (es) Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida.
WO2001049823A3 (en) Assays for detection of bacillus anthracis
WO2003061570A3 (en) Engineered binding proteins
WO2008098115A3 (en) Optimized igf-1r antibodies and methods of using the same
EP2186884A3 (de) Monoklonale Antikörpergegen HCV Kernantigen
WO2007063415A3 (en) Methods of producing stable b-lymphocytes
AU2003209059A1 (en) Human monoclonal antibodies against membrane proteins
IL169804A (en) 254p1d6b proteins, nucleic acids encoding the same, processes for producing the same, antibodies binding thereto and uses thereof
WO2002036738A3 (en) Affinity maturation by competitive selection
WO2000050607A3 (en) Goodpasture antigen binding protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002745239

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002583452

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2002745239

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10475147

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2002745239

Country of ref document: EP